CN115137766B - Preparation method of anti-rheumatism traditional Chinese medicine preparation, traditional Chinese medicine preparation and application - Google Patents
Preparation method of anti-rheumatism traditional Chinese medicine preparation, traditional Chinese medicine preparation and application Download PDFInfo
- Publication number
- CN115137766B CN115137766B CN202210963560.1A CN202210963560A CN115137766B CN 115137766 B CN115137766 B CN 115137766B CN 202210963560 A CN202210963560 A CN 202210963560A CN 115137766 B CN115137766 B CN 115137766B
- Authority
- CN
- China
- Prior art keywords
- parts
- preparation
- extract
- chinese medicine
- traditional chinese
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 69
- 238000002360 preparation method Methods 0.000 title claims abstract description 62
- 241000218176 Corydalis Species 0.000 claims abstract description 19
- 241000382455 Angelica sinensis Species 0.000 claims abstract description 17
- 241000208152 Geranium Species 0.000 claims abstract description 17
- 235000007866 Chamaemelum nobile Nutrition 0.000 claims abstract description 16
- 244000042664 Matricaria chamomilla Species 0.000 claims abstract description 16
- 235000007232 Matricaria chamomilla Nutrition 0.000 claims abstract description 16
- 244000303040 Glycyrrhiza glabra Species 0.000 claims abstract description 14
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 14
- 241000501743 Gentiana macrophylla Species 0.000 claims abstract description 13
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims abstract description 12
- 235000011477 liquorice Nutrition 0.000 claims abstract description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 121
- 239000000284 extract Substances 0.000 claims description 87
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 48
- 239000000843 powder Substances 0.000 claims description 46
- 238000000034 method Methods 0.000 claims description 32
- 238000000605 extraction Methods 0.000 claims description 31
- 239000002994 raw material Substances 0.000 claims description 24
- 239000008187 granular material Substances 0.000 claims description 21
- 238000010992 reflux Methods 0.000 claims description 21
- 239000000463 material Substances 0.000 claims description 18
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 15
- 239000006286 aqueous extract Substances 0.000 claims description 13
- 238000007670 refining Methods 0.000 claims description 13
- 238000001035 drying Methods 0.000 claims description 11
- 239000007788 liquid Substances 0.000 claims description 11
- 238000011282 treatment Methods 0.000 claims description 9
- 238000002156 mixing Methods 0.000 claims description 8
- 239000006228 supernatant Substances 0.000 claims description 8
- 239000002775 capsule Substances 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 239000002552 dosage form Substances 0.000 claims description 3
- 239000000469 ethanolic extract Substances 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- 235000001287 Guettarda speciosa Nutrition 0.000 claims description 2
- 244000061520 Angelica archangelica Species 0.000 claims 1
- 241000628997 Flos Species 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 26
- 208000002193 Pain Diseases 0.000 abstract description 15
- 239000003435 antirheumatic agent Substances 0.000 abstract description 6
- 230000003356 anti-rheumatic effect Effects 0.000 abstract description 4
- 230000003213 activating effect Effects 0.000 abstract description 3
- 230000000052 comparative effect Effects 0.000 description 33
- 239000000243 solution Substances 0.000 description 32
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 20
- 238000010521 absorption reaction Methods 0.000 description 14
- 229940079593 drug Drugs 0.000 description 14
- 239000000945 filler Substances 0.000 description 13
- 239000000203 mixture Substances 0.000 description 11
- 239000002245 particle Substances 0.000 description 11
- 239000011230 binding agent Substances 0.000 description 10
- 238000001514 detection method Methods 0.000 description 10
- 229940074391 gallic acid Drugs 0.000 description 10
- 235000004515 gallic acid Nutrition 0.000 description 10
- 238000005303 weighing Methods 0.000 description 9
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 description 8
- DUAGQYUORDTXOR-GPQRQXLASA-N Gentiopicrin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@H](C=C)C2=CCOC(=O)C2=CO1 DUAGQYUORDTXOR-GPQRQXLASA-N 0.000 description 8
- DUAGQYUORDTXOR-WULZUDSJSA-N Gentiopicrin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@H]1[C@@H](C=C)C=2C(C(=O)OCC=2)=CO1 DUAGQYUORDTXOR-WULZUDSJSA-N 0.000 description 8
- HPUXDMUGCAWDFW-UHFFFAOYSA-N Osthole Natural products COc1ccc2CCC(=O)Oc2c1C=CC(=O)C HPUXDMUGCAWDFW-UHFFFAOYSA-N 0.000 description 8
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 description 8
- 229940114124 ferulic acid Drugs 0.000 description 8
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 description 8
- 235000001785 ferulic acid Nutrition 0.000 description 8
- MBRLOUHOWLUMFF-UHFFFAOYSA-N osthole Chemical compound C1=CC(=O)OC2=C(CC=C(C)C)C(OC)=CC=C21 MBRLOUHOWLUMFF-UHFFFAOYSA-N 0.000 description 8
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 description 8
- 239000004480 active ingredient Substances 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 150000004676 glycans Chemical class 0.000 description 7
- 210000001503 joint Anatomy 0.000 description 7
- 229920001282 polysaccharide Polymers 0.000 description 7
- 239000005017 polysaccharide Substances 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- 239000012675 alcoholic extract Substances 0.000 description 6
- 239000002131 composite material Substances 0.000 description 6
- 239000012535 impurity Substances 0.000 description 6
- 238000003809 water extraction Methods 0.000 description 6
- 238000003745 diagnosis Methods 0.000 description 5
- 238000005469 granulation Methods 0.000 description 5
- 230000003179 granulation Effects 0.000 description 5
- 230000014759 maintenance of location Effects 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 238000000465 moulding Methods 0.000 description 5
- 238000001556 precipitation Methods 0.000 description 5
- 239000013558 reference substance Substances 0.000 description 5
- 238000004062 sedimentation Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 239000000853 adhesive Substances 0.000 description 4
- 230000001070 adhesive effect Effects 0.000 description 4
- 238000005352 clarification Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000000857 drug effect Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 239000007779 soft material Substances 0.000 description 4
- 210000002435 tendon Anatomy 0.000 description 4
- 238000001291 vacuum drying Methods 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 208000006820 Arthralgia Diseases 0.000 description 3
- 229920001661 Chitosan Polymers 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 238000000703 high-speed centrifugation Methods 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000011056 performance test Methods 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 239000012488 sample solution Substances 0.000 description 3
- 238000007873 sieving Methods 0.000 description 3
- 238000001179 sorption measurement Methods 0.000 description 3
- 238000005728 strengthening Methods 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 241001166194 Geranium wilfordii Species 0.000 description 2
- 206010023232 Joint swelling Diseases 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 241000208829 Sambucus Species 0.000 description 2
- 235000018735 Sambucus canadensis Nutrition 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 235000007123 blue elder Nutrition 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000008395 clarifying agent Substances 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 235000007124 elderberry Nutrition 0.000 description 2
- 235000008995 european elder Nutrition 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000003862 glucocorticoid Substances 0.000 description 2
- 229960001031 glucose Drugs 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000002791 soaking Methods 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229940037128 systemic glucocorticoids Drugs 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- 241000125175 Angelica Species 0.000 description 1
- 206010071155 Autoimmune arthritis Diseases 0.000 description 1
- 208000010392 Bone Fractures Diseases 0.000 description 1
- 108010074051 C-Reactive Protein Proteins 0.000 description 1
- 102100032752 C-reactive protein Human genes 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 1
- 235000017443 Hedysarum boreale Nutrition 0.000 description 1
- 235000007858 Hedysarum occidentale Nutrition 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010023203 Joint destruction Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010062237 Renal impairment Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 240000006322 Sambucus chinensis Species 0.000 description 1
- 235000010426 Sambucus chinensis Nutrition 0.000 description 1
- 206010067868 Skin mass Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- -1 emplastrum Substances 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 208000018937 joint inflammation Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 229940010454 licorice Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 238000004513 sizing Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 229940043263 traditional drug Drugs 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 210000000707 wrist Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/35—Caprifoliaceae (Honeysuckle family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/51—Gentianaceae (Gentian family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/66—Papaveraceae (Poppy family), e.g. bloodroot
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1664—Compounds of unknown constitution, e.g. material from plants or animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Botany (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Zoology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention provides a preparation method of an antirheumatic traditional Chinese medicine preparation, a traditional Chinese medicine preparation and application, wherein the traditional Chinese medicine preparation comprises 14-16 parts of geranium, 5-7 parts of liquorice, 11-13 parts of radix angelicae pubescentis, 11-13 parts of gentiana macrophylla, 9-11 parts of elder, 9-11 parts of rhizoma corydalis, 9-11 parts of angelica sinensis and 7-9 parts of chamomile according to parts by weight, and has the effects of dispelling wind-cold dampness and clearing and activating the channels and collaterals to relieve pain.
Description
Technical Field
The invention relates to the technical field of traditional Chinese medicines, in particular to a preparation method of an antirheumatic traditional Chinese medicine preparation, a traditional Chinese medicine preparation and application.
Background
Rheumatoid arthritis is an autoimmune arthritis, often causes joint destruction and deformity, is easy to cause various complications, seriously affects the life quality of patients, has high morbidity and disability rate, has long disease course, and has great harm to physical and mental health of patients. The main purpose of rheumatoid arthritis treatment is to reduce joint inflammation, inhibit lesion development and irreversible bone destruction, protect functions of joints and muscles as much as possible, and finally achieve the aim of completely relieving illness state or reducing illness activity. At present, non-steroidal anti-inflammatory drugs, glucocorticoids, biological agents and the like are mostly adopted for Western medicine treatment, but the drugs can only be used as auxiliary treatment, and long-term use of the drugs can not improve disease development and can also cause serious side effects. One trend in current rheumatoid therapy is to shift to biological antirheumatic drug therapy and traditional drug therapy to prevent and delay progression of joint damage in patients. The Chinese medicine has the functions of multiple layers, multiple components and multiple targets, so that the Chinese patent medicine has certain advantages in treating the disease.
The compound geranium wilfordii recipe is a traditional meridian recipe for treating rheumatism by Kazakhstan, and has the effects of dispelling wind-cold-dampness, dredging meridian passage and relieving pain. The traditional Chinese medicine compound is inconvenient to carry and use, has unstable drug effect and other technical problems, and causes great barriers to the use and popularization of the compound geranium formula, and the research on the process of the compound geranium formula preparation is not reported in the prior art. Although the prior art has the technical proposal of the extraction process of the traditional Chinese medicine decoction pieces, a great amount of impurities and macromolecular substances are usually accompanied while the ingredients are obtained, so that patients need to take larger dosage to ensure the curative effect when taking the traditional Chinese medicine decoction pieces. In addition, because the extract powder has stronger hygroscopicity, excessive instability can be shown in the actual production process of the preparation, and although the hygroscopicity of the extract can be reduced to a certain extent by adding auxiliary materials, the effect is often poor, and the addition of the auxiliary materials can also increase the volume of the preparation, so that the dosage of patients is increased. Therefore, a preparation which not only ensures curative effect, but also is convenient to carry and use and controllable and stable in quality needs to be developed.
Disclosure of Invention
In order to solve the technical problems, the invention aims to provide a preparation method of an anti-rheumatism traditional Chinese medicine preparation, the traditional Chinese medicine preparation and application.
In order to achieve the above object, the present invention provides the following technical solutions:
the preparation method of the anti-rheumatism traditional Chinese medicine preparation comprises the following raw materials in parts by weight:
14-16 parts of geranium, 5-7 parts of liquorice, 11-13 parts of radix angelicae pubescentis, 11-13 parts of gentiana macrophylla, 9-11 parts of elder, 9-11 parts of rhizoma corydalis, 9-11 parts of angelica sinensis and 7-9 parts of chamomile;
the preparation method comprises the following steps:
taking geranium, liquorice and chamomile according to parts by weight, extracting with water under reflux, and refining to obtain an aqueous extract;
reflux-extracting radix Gentianae Marcrophyllae, radix Angelicae sinensis, ramulus Sambuci Williamsii, rhizoma corydalis and radix Angelicae Pubescentis with ethanol solution to obtain ethanol extract;
concentrating the water extract and the alcohol extract under reduced pressure respectively, drying to obtain extract fine powder, adding binder and part of raw material fine powder, mixing and granulating.
Preferably, the refining comprises: concentrating the water extract under reduced pressure until the ratio of the mass of the medicinal materials to the volume of the liquid medicine is 1 (1-1.2), standing, and filtering to obtain supernatant.
Preferably, the amount of the part of raw material fine powder is 5-10% of the total weight of the extract fine powder.
Preferably, the partial raw material is selected from one or two of angelica and radix angelicae pubescentis.
Preferably, the binder is an ethanol solution with a concentration of 92-93%.
Preferably, the concentration of the ethanol solution is 65-75%, the volume of the added ethanol solution is 9-11 times of the weight of the raw materials, the reflux extraction is carried out for 1-3 times, and each time of extraction is 80-120 min.
Preferably, the temperature of the reduced pressure concentration is 60-80 ℃.
Preferably, the drying temperature is 60-80 ℃.
The invention also provides a traditional Chinese medicine preparation prepared by the preparation method.
Preferably, the traditional Chinese medicine preparation is in the form of granules.
The invention also provides application of the traditional Chinese medicine preparation in preparing a medicine for treating rheumatoid arthritis.
Compared with the prior art, the invention has the following beneficial effects:
(1) According to the preparation method, the natural sedimentation method is used for removing impurities and refining the water extract, so that the cost is low, compared with other impurity removing methods such as the water extraction and alcohol sedimentation method, the high-speed centrifugation method, the clarifier adsorption method and the like, the impurity removing effect is better, the effective components can be reserved to the greatest extent, and meanwhile, the production cost is lower.
(2) The preparation method only uses part of raw material fine powder as a filler, can reduce the moisture absorption rate of the extract and increase the stability of the preparation production process. In addition, as only part of raw material fine powder is used as the filling agent, the finally prepared preparation does not contain other auxiliary materials irrelevant to the drug effect, and the dosage of patients is reduced.
(3) The solvent dosage, the extraction time, the extraction temperature and the drying temperature in the preparation method can furthest extract the effective components in the raw materials, improve the drug effect of the preparation and reduce the dosage of patients.
(4) The traditional Chinese medicine preparation has the effects of dispelling wind-cold-dampness, clearing and activating the channels and collaterals and relieving pain, has obvious curative effect and has unique advantages for treating rheumatoid arthritis.
Detailed Description
The invention provides a preparation method of an antirheumatic traditional Chinese medicine preparation, the traditional Chinese medicine preparation and application, and all raw material components are commercial products well known to those skilled in the art unless specified.
In the invention, the preparation method comprises the following raw materials in parts by weight: 14-16 parts of geranium, 5-7 parts of liquorice, 11-13 parts of radix angelicae pubescentis, 11-13 parts of gentiana macrophylla, 9-11 parts of sambucus chinensis, 9-11 parts of rhizoma corydalis, 9-11 parts of angelica sinensis and 7-9 parts of chamomile, and the preparation method is that: 15 parts of geranium, 6 parts of liquorice, 12 parts of radix angelicae pubescentis, 12 parts of gentiana macrophylla, 10 parts of elder, 10 parts of rhizoma corydalis, 10 parts of angelica sinensis and 8 parts of chamomile.
In the invention, the medicines are used in proportion to have the effects of dispelling wind, dredging collaterals and strengthening tendons and bones. Specifically, the geranium wilfordii is bitter and flat, has the effects of dispelling wind and dredging collaterals, strengthening tendons and bones, and tonifying middle-jiao and xies, and is a monarch drug. Qin Marcrophylla is good at dispelling wind-dampness, relaxing tendons and activating collaterals, relieving joint pain, and penetrating skin to exogenous pathogenic factors; radix Angelicae Pubescentis, with pungent and warm natured drugs, is good at dispelling pathogenic wind, cold and dampness from joints; chamomile has the effects of diminishing inflammation and relieving pain, and the chamomile, the chamomile and the chamomile are all ministerial drugs. Rhizoma corydalis has effects of promoting blood circulation, removing blood stasis and relieving pain; bone fracture setting, tendon reunion, blood circulation promoting, pain relieving, wind dispelling and dampness eliminating effects are taken as adjuvant drugs; dang Gui is a drug for regulating blood. Licorice root, radix Glycyrrhizae has the effects of clearing heat and detoxicating, relieving spasm and pain, and harmonizing other drugs, and has the actions of tonifying and strengthening qi, and is a side-effect drug. The seven medicines together play the roles of dispelling wind-cold dampness, dredging the meridian passage and relieving pain.
The preparation method of the invention comprises the following steps:
taking geranium, liquorice and chamomile according to parts by weight, extracting with water under reflux, and refining to obtain an aqueous extract;
reflux-extracting radix Gentianae Marcrophyllae, radix Angelicae sinensis, ramulus Sambuci Williamsii, rhizoma corydalis and radix Angelicae Pubescentis with ethanol solution to obtain ethanol extract;
concentrating and drying the water extract and the alcohol extract respectively to obtain extract fine powder, adding the adhesive and part of raw material fine powder, mixing and granulating.
In the invention, the geranium, the chamomile and the liquorice are extracted by water reflux, so that the main components of gallic acid in the geranium, polysaccharide in the liquorice and flavonoid active substances rich in the chamomile are obtained, and the components can regulate inflammatory factors and play an anti-inflammatory role.
Specifically, the water reflux extraction comprises the following steps: soaking geranium, liquorice and chamomile in water with the volume of 8-12 times of the weight of the raw materials for 90-150 min, and reflux-extracting for 1-3 times, wherein each time is 60-120 min. In the water reflux extraction, the water addition ratio is preferably 10 to 12 times, more preferably 11 times. The soaking time is preferably 120 to 150min, more preferably 130min. The number of times of the reflux extraction is preferably 2 to 3 times, more preferably 2 times. The time for each extraction is preferably 60 to 100min, more preferably 90min.
In the invention, the geranium, licorice and jersey Gan Jushui extract needs to be refined, so as to remove impurities and macromolecular components irrelevant to the drug effect, reduce the extract yield, improve the product quality and reduce the dosage of patients. At present, the impurity removal refining is carried out by adopting methods such as a water extraction and alcohol precipitation method, a macroporous resin adsorption method, a high-speed centrifugation method, an adsorption clarification method and the like in the industry, but researches show that compared with other methods such as a water extraction and alcohol precipitation method, a high-speed centrifugation method, a clarifier method and the like, the method can furthest retain the index components in the traditional Chinese medicine extract and can furthest reduce the extract yield by using a natural sedimentation method.
Specifically, the natural sedimentation method comprises the following steps: concentrating the water extract under reduced pressure to obtain medicinal materials: 1 to 1.2 percent of liquid medicine, and filtering and taking supernatant after standing. The medicinal materials are as follows: the liquid medicine refers to the ratio of the weight of solute in the water extract to the volume of the liquid medicine, and is preferably 1:1.1. Preferably, the pressure of the reduced pressure concentration is-0.08 to 0.07Mpa. Preferably, the temperature of the reduced pressure concentration is 60 to 80 ℃, more preferably 65 to 75 ℃, and even more preferably 70 ℃. As an alternative embodiment, the temperature of the standing may be 2 to 8 ℃, preferably 4 ℃, and the time of the standing may be 20 to 30 hours, preferably 24 hours.
In the invention, gentiana macrophylla, angelica sinensis, elderberry, rhizoma corydalis and radix angelicae pubescentis are extracted by an alcohol extraction method, so that the active ingredients of ferulic acid in angelica sinensis, osthole in radix angelicae pubescentis, gentiopicroside in gentiana macrophylla, iridoid compounds in elderberry and alkaloids in rhizoma corydalis are obtained, and the above ingredients have the effects of anti-inflammatory, analgesic, rheumatoid arthritis treatment and the like.
Specifically, the ethanol reflux extraction comprises the following steps: mixing radix gentianae macrophyllae, chinese angelica, elder, rhizoma corydalis and radix angelicae pubescentis, adding ethanol solution with the volume of 9-11 times of the weight of the raw materials and the concentration of 65-75%, and carrying out reflux extraction for 1-3 times, wherein each time of extraction is 80-100 min. The multiple of the addition of the ethanol solution is preferably 10 times. The concentration of the ethanol solution is preferably 70%. The number of reflux extractions is preferably 2 to 3, more preferably 2. The time for each extraction is preferably 90min.
Preferably, the alcohol extract and the refined water extract are respectively concentrated under reduced pressure at 60-80 ℃ and-0.08-0.07 Mpa until the relative density is 1.20-1.25 and 1.15-1.20, then are dried under vacuum at 60-80 ℃ to respectively obtain alcohol extract and water extract dry extract, the dry extract is crushed and sieved to obtain fine powder, the fine powder is uniformly mixed with auxiliary materials, and the mixture is added with an adhesive for granulating. Preferably, the fine powder of the dry extract is required to pass through a 80-100 mesh sieve.
In the present invention, the temperature at which the alcohol extract and the aqueous extract are concentrated under reduced pressure is 60 to 80 ℃, preferably 65 to 75 ℃, more preferably 70 ℃. The temperature of the vacuum drying is 60 to 80 ℃, preferably 65 to 75 ℃, more preferably 70 ℃. According to the invention, the contents of ferulic acid, osthole and gentiopicroside in the alcohol extract and the content of gallic acid in the water extract are high in the temperature range, the loss is minimum, and the content is reduced when the temperature range is exceeded.
In the invention, only part of fine powder of medicinal raw materials is used as a filler. Firstly, the content of active ingredients in the preparation can be increased by using the medicine fine powder as a filling agent, so that the addition of ingredients irrelevant to the medicine effect is reduced; and secondly, researches show that the hygroscopicity of the extract is too strong, and only part of the fine powder of the raw material medicaments in the formula is added as a filler, so that the problem of the strong hygroscopicity of the fine powder of the extract can be effectively solved, the forming rate and the mobile phase are improved, and the stability of the preparation is improved compared with other types of fillers such as sucrose and CMC-Na.
Specifically, the fine powder of part of the medicinal materials is selected from one or more of herba Erodii seu Geranii, glycyrrhrizae radix, radix Angelicae Pubescentis, radix Gentianae Marcrophyllae, ramulus Sambuci Williamsii, rhizoma corydalis, and radix Angelicae sinensis, preferably radix Angelicae sinensis and/or radix Angelicae Pubescentis, and more preferably radix Angelicae Pubescentis. Preferably, the fine powder of the medicinal materials is sieved by a sieve of 80-100 meshes. The addition amount of the medicinal fine powder is 5-10% of the total dry extract, preferably 6-9%, more preferably 8% by weight.
In the present invention, an ethanol solution having a concentration of 92 to 93% is preferably used as the binder, and an ethanol solution having a concentration of 93% is more preferably used. The preparation method provided by the invention only uses part of medicinal material raw material fine powder as a filler, does not use other types of fillers such as starch, dextrin, sucrose and the like, and does not add other auxiliary materials except the medicinal material fine powder and the ethanol solution, so when the ethanol solution is used as a binder, the concentration of the ethanol is very critical, the difficulty degree of granulation, the appearance of particles and the like can be influenced due to too high or too low concentration, the problems of over-adhesion, difficult particle sizing, difficult sieving and the like occur due to too low concentration of the ethanol solution, the soft material is too dry due to too high concentration of the ethanol, the particles are loose, too much fine powder, and the granulation cannot be completed due to too high or too low concentration.
The invention provides an antirheumatic traditional Chinese medicine preparation, which is prepared by the preparation method. As an alternative embodiment, the formulation contains the particles obtained by the above preparation method and a pharmaceutically acceptable carrier. Preferably, the dosage form can be an oral preparation, can be granules, capsules, emplastrum, tablets, sustained-release preparations or the like, and more preferably, the dosage form is granules.
The invention also provides application of the traditional Chinese medicine preparation in preparing a medicine for treating rheumatoid arthritis.
The technical solutions of the present invention will be clearly and completely described in the following in connection with the embodiments of the present invention. It will be apparent that the described embodiments are only some, but not all, embodiments of the invention. All other embodiments, which can be made by those skilled in the art based on the embodiments of the invention without making any inventive effort, are intended to be within the scope of the invention.
Example 1
15g of geranium, 6g of liquorice and 8g of chamomile are taken according to parts by weight, 11 times of water is added, the mixture is soaked for 130min, reflux extraction is carried out for 2 times, each time of extraction is carried out for 90min, and the water extract is decompressed and concentrated to the medicinal materials at 70 ℃: the liquid medicine is 1:1.1, and the supernatant is filtered after being placed for 24 hours under the low temperature environment of 4 ℃.
Taking 12g of gentiana macrophylla, 10g of Chinese angelica, 10g of elder, 10g of rhizoma corydalis and 12g of radix angelicae pubescentis according to parts by weight, crushing part of radix angelicae pubescentis raw materials, sieving with a 90-mesh sieve to obtain radix angelicae pubescentis fine powder, mixing the rest raw materials, adding 10 times of 70% ethanol solution, carrying out reflux extraction for 2 times, and extracting for 90min each time.
Concentrating the water extract and the alcohol extract at 70 ℃ under reduced pressure respectively until the relative density is 1.15-1.20 and 1.20-1.25, then drying in vacuum at 70 ℃, and crushing to obtain extract fine powder. Taking 93% ethanol solution as binder, adding extract fine powder and radix Angelicae Pubescentis fine powder of 8% of the weight of the extract powder, mixing, and granulating to obtain granule.
Example 2
The preparation method was the same as in example 1, except that after the completion of granulation, the granules were filled into capsules to prepare capsules.
Example 3
Compared with the example 1, the gentiana macrophylla, the angelica sinensis, the elder, the rhizoma corydalis and the radix angelicae pubescentis are mixed and then added with 10 times of 70% ethanol solution, and the mixture is extracted under reflux for 3 times, each time for 90min, and the rest are the same.
Example 4
Compared with the example 1, the water extract is decompressed and concentrated to the medicinal materials at 70 ℃ during the refining: the liquid medicine is 1:1, the liquid medicine is placed for 24 hours under the low temperature environment of 4 ℃ and then filtered, the supernatant is taken, and the rest are the same.
Example 5
Compared with the example 1, the water extract is decompressed and concentrated to the medicinal materials at 70 ℃ during the refining: the liquid medicine is 1:2, the liquid medicine is placed for 24 hours under the low temperature environment of 4 ℃ and then filtered, the supernatant is taken, and the rest are the same.
Example 6
In comparison with example 1, the aqueous extract and the alcoholic extract were concentrated under reduced pressure at 60℃respectively, the remainder being the same.
Example 7
In comparison with example 1, the concentrated aqueous and alcoholic extracts were dried at 60℃under vacuum, the remainder being the same.
Example 8
In comparison with example 1, an ethanol solution having a concentration of 92% was used as a binder, and the remainder were the same.
Example 9
The amount of the fine powder of radix Angelicae Pubescentis added was 10% as compared with example 1, and the rest was the same.
Example 10
Compared with the example 1, the rest part of the Chinese angelica raw material is crushed and passes through a 90-mesh screen, the dosage is 8% of the weight of the extract powder, and the rest is the same.
Example 11
Compared with example 1, the rest part of the Chinese angelica and the radix angelicae pubescentis fine powder are crushed and pass through a 90-mesh screen, and the Chinese angelica fine powder accounting for 5% of the weight of the extract powder and the radix angelicae pubescentis fine powder accounting for 5% of the weight of the extract powder are used as filling agents, and the rest parts are the same.
Example 12
The preparation method was the same as in example 1 except that after the completion of granulation, the granules were compressed into tablets and prepared into tablets.
Example 13
15g of geranium, 6g of liquorice and 8g of chamomile are taken according to parts by weight, 11 times of water is added, the mixture is soaked for 130min, reflux extraction is carried out for 2 times, each time of extraction is carried out for 90min, and the water extract is decompressed and concentrated to the medicinal materials at 70 ℃: the liquid medicine is 1:1.1, and the supernatant is filtered after being placed for 24 hours under the low temperature environment of 4 ℃.
Taking 12g of gentiana macrophylla, 10g of Chinese angelica, 10g of elder, 10g of rhizoma corydalis and 12g of radix angelicae pubescentis according to parts by weight, crushing part of radix angelicae pubescentis raw materials, sieving with a 90-mesh sieve to obtain radix angelicae pubescentis fine powder, mixing the rest raw materials, adding 10 times of 70% ethanol solution, carrying out reflux extraction for 2 times, and extracting for 90min each time.
Concentrating the water extract and the alcohol extract at 70 ℃ under reduced pressure respectively until the relative density is 1.15-1.20 and 1.20-1.25, then drying in vacuum at 70 ℃, and crushing to obtain extract fine powder. Adding 580g vaseline into the extract fine powder and radix Angelicae Pubescentis fine powder with weight of 8% of the extract powder, stirring to obtain Chinese medicinal paste, spreading the Chinese medicinal paste (thickness 1.5cm, diameter 8 cm) on plaster cloth, and making into Chinese medicinal patch.
Comparative example 1
Compared with the example 1, the gentiana macrophylla, the angelica sinensis, the elder, the rhizoma corydalis and the radix angelicae pubescentis are mixed and then added with 8 times of 80% ethanol solution, and the mixture is extracted for 2 times under reflux, each time for 90min, and the rest are the same.
Comparative example 2
Compared with the example 1, the gentiana macrophylla, the angelica sinensis, the elder, the rhizoma corydalis and the radix angelicae pubescentis are mixed and then added with 10 times of 80% ethanol solution, and the mixture is subjected to reflux extraction for 2 times, each time for 120min, and the rest are the same.
Comparative example 3
Compared with the example 1, the gentiana macrophylla, the angelica sinensis, the elder, the rhizoma corydalis and the radix angelicae pubescentis are mixed and then added with 12 times of 70% ethanol solution, and the mixture is subjected to reflux extraction for 2 times, each time for 120min, and the rest are the same.
Comparative example 4
Compared with example 1, the aqueous extract was purified by centrifugation at 3000rpm for 20min to obtain a supernatant filtrate, and the remainder were the same.
Comparative example 5
Compared with example 1, the water extract was purified by water extraction and alcohol precipitation, absolute ethanol was added to the water extract to a concentration of 60%, and the mixture was left to stand at 4℃for 24 hours and filtered, and the rest was the same.
Comparative example 6
Compared with the example 1, the water extract is refined by using a chitosan clarification method, the chitosan solution with the volume of 4% of the water extract is slowly added into the water extract in a trickle way, the water extract is uniformly mixed and then is put into a water bath kettle with the temperature of 60 ℃ for heat preservation for 1h, then is kept stand for 24h at the low temperature of 4 ℃ and then is filtered, and the rest is the same.
Comparative example 7
Compared with the example 1, the ZTC1+1-II natural clarifying method is used for refining the water extract, the natural clarifying agent A component accounting for 8% of the volume of the water extract is slowly added firstly, then the water extract is put into a water bath at 60 ℃ for 1h and then is taken out, the natural clarifying agent B component accounting for 4% of the volume of the water extract is slowly added, then the water extract is put into the water bath at 60 ℃ for 1h and then is taken out, the water extract is kept stand for 24h in a low-temperature environment at 4 ℃ and is filtered, and the rest is the same.
Comparative example 8
In comparison with example 1, the aqueous extract and the alcoholic extract were concentrated under reduced pressure at 50℃respectively, the remainder being the same.
Comparative example 9
In comparison with example 1, the aqueous extract and the alcoholic extract were concentrated under reduced pressure at 90℃respectively, the remainder being the same.
Comparative example 10
In comparison with example 1, the concentrated aqueous extract and the alcoholic extract were dried at 50℃under vacuum, the remainder being the same.
Comparative example 11
In comparison with example 1, the concentrated aqueous extract and the alcoholic extract were dried at 90℃under vacuum, the remainder being the same.
Comparative example 12
In comparison with example 1, ethanol with a concentration of 88% was used as binder, the remainder being the same.
Comparative example 13
In comparison with example 1, ethanol with a concentration of 95% was used as binder, the remainder being the same.
Comparative example 14
Compared with example 1, 10% of sucrose was used as filler based on the total weight of the dry extract, and the rest was the same.
Comparative example 15
In comparison with example 1, lactose was used as filler in an amount of 10% by weight based on the total weight of the dry extract, the remainder being the same.
Comparative example 16
As compared with example 1, CMC-Na was used as filler in an amount of 10% by weight based on the total dry extract weight, the remainder being the same.
Test example 1
1. Detection method
(1) Determination of extractum yield
Placing 50mL of sample solution into a dried constant-weight evaporation dish, evaporating to dryness, transferring into a 105 ℃ oven for drying for 3 hours, placing into a dryer for cooling and drying for 1 hour, precisely weighing, and calculating the extract yield according to the following formula:
(2) Method for measuring gentiopicroside content in extract
The measurement was performed by high performance liquid chromatography, and the chromatographic conditions and standard information were as follows:
chromatographic column: agilent C18, 250mm x 4.6mm,5 μm; mobile phase: methanol-water= (22:78); sample injection amount: 5. Mu.L; volume flow rate: 1.0mL/min; column temperature: 30 ℃; detection wavelength: 270nm; the gentiopicroside reference substance is provided by Chinese food and drug verification institute, and has batch number of 110770-201918.
(3) Method for measuring content of ferulic acid and osthole in extract
The measurement was performed by high performance liquid chromatography, and the chromatographic conditions and standard information were as follows:
chromatographic column: agilent C18 column, 250mm 4.6mm,5 μm; the mobile phases A and B are acetonitrile and 0.1% phosphoric acid solution mobile phases respectively, and gradient elution is carried out; sample injection amount: 10. Mu.L; volume flow rate: 1.0mL/min; detection wavelength: 320nm; column temperature: 30 ℃; the reference substance is provided by Chinese food and drug verification institute, with ferulic acid batch number 110773-201614, osthole batch number 110822-201710.
(4) Method for measuring gallic acid content in water extract
The measurement was performed by high performance liquid chromatography, and the chromatographic conditions and standard information were as follows:
chromatographic column: agilent C18, 250mm x 4.6mm,5 μm; mobile phase: methanol-0.2% phosphoric acid (5:95); sample injection amount: 5L; volume flow rate: 1.0mL/min; detection wavelength: 266nm; gallic acid reference substance is provided by Chinese food and drug inspection institute, and has batch number of 110831-201605.
(5) Determination of the content of Total polysaccharide
The total polysaccharide content was determined using uv-vis spectrophotometry. Taking a proper amount of D-anhydrous glucose reference substance, precisely weighing, placing into a 10mL volumetric flask, and fixing the volume to a scale with pure water to obtain a reference substance solution.
And precisely transferring 0.3mL of the sample solution, 0.3mL of the D-anhydrous glucose control solution by a pipette, placing the sample solution in a 10mL glass test tube, adding 1mL of 5% phenol solution and 5mL of concentrated sulfuric acid solution, mixing, standing for 10min, then placing the test tube in boiling water, heating for 20min, taking out the test tube, rapidly cooling the mixture to room temperature by cold water, and detecting absorbance at 483.2 nm. The content was calculated by standard curve method.
(6) Measurement of Forming Rate
And weighing a proper amount of prepared compound geranium granules, and calculating the forming rate by taking the qualified compound geranium granules which pass through a No. 1 sieve and cannot pass through a No. 5 sieve.
Molding rate (%) =acceptable pellet weight/total pellet weight×100%.
(7) Determination of moisture absorption Rate
And (3) taking a saturated sodium chloride solution dryer, placing the dryer in a constant temperature incubator at 25 ℃ for 24 hours, and placing a temperature and humidity recorder in the dryer to keep the internal humidity of the vessel constant at 75%. Precisely weighing 2g of uniformly mixed particles, placing the uniformly mixed particles in a constant-weight flat weighing bottle, precisely weighing the total weight, placing the obtained product in the dryer (25 ℃, opening the bottle cap), fully absorbing moisture by the particles after 2 days, and calculating the moisture absorption rate.
Moisture absorption (%) = (weight after moisture absorption-weight before moisture absorption)/weight before moisture absorption×100%.
(8) Measurement of the angle of repose
And (3) taking a saturated sodium chloride solution dryer, placing the dryer in a constant temperature incubator at 25 ℃ for 24 hours, and placing a temperature and humidity recorder in the dryer to keep the internal humidity of the vessel constant at 75%. Precisely weighing 2g of uniformly mixed particles, placing the uniformly mixed particles in a constant-weight flat weighing bottle, precisely weighing the total weight, placing the obtained product in the dryer (25 ℃, opening the bottle cap), fully absorbing moisture by the particles after 2 days, and calculating the moisture absorption rate.
Moisture absorption (%) = (weight after moisture absorption-weight before moisture absorption)/weight before moisture absorption×100%.
2. Detection result
(1) Alcohol extraction process performance detection result
The composite score is calculated according to the following formula:
composite score = gentiopicroside/maximum content x 0.4+ ferulic acid/maximum content x 0.2+ osthole/maximum content x 0.2+ extract yield/maximum extract amount x 0.2
TABLE 1 results of alcohol extraction Process Performance test
As can be seen from Table 1, the three active ingredients of ferulic acid, osthole and gentiopicroside in the extract obtained by the alcohol extraction process of examples 1 and 3 have high contents, and the comprehensive score is above 95. Comparative examples 1 to 3 were lower in the content of three active ingredients in the extract than examples 1 and 3 due to unsuitable ethanol concentration, extraction time and fold of the ethanol solution. It can be seen that the effect of the alcohol extraction process of the present invention is superior to that of comparative examples 1 to 3.
(2) Performance test results of refining method
The composite score is calculated according to the following formula:
comprehensive score = gallic acid retention/maximum retention value x 0.4+ total polysaccharide retention/maximum retention value x 0.3+ extract yield reduction rate/maximum reduction rate x 0.3
Table 2 results of refining process performance test
As can be seen from Table 2, the refining methods of examples 1, 4 and 5 can effectively reduce the extract yield, and retain gallic acid and polysaccharide in the aqueous extract to the maximum extent, and the comprehensive scores are above 90. Comparative examples 4 to 7 used centrifugation, water extraction and alcohol precipitation, chitosan clarification and ZTC1+1-II natural clarification, respectively, and the effects of lowering the extract yields of comparative examples 4, 6 and 7 were not satisfactory, and the retention of gallic acid and total polysaccharides were not as good as in examples 1, 4 and 5. Comparative example 5 uses the water extraction and alcohol precipitation method, and the extract is reduced similar to that of example 1, but the loss of gallic acid and polysaccharide as active ingredients is too high. It can be seen that the technical effects of the present invention are superior to those of comparative examples 4 to 7.
(3) Performance results of reduced pressure concentration temperature
TABLE 3 detection results of reduced pressure concentration temperature
As can be seen from Table 3, the alcohol extracts of examples 1 and 6 were high in ferulic acid, osthole, gentiopicroside and gallic acid in the water body, wherein the content of the above components was the highest in example 1. The temperatures of comparative examples 8 and 9 were too low and too high, respectively, and the contents of the active ingredients in the extracts were lower than those of examples 1 and 6. It can be seen that the technical effect of the concentration process of the present invention is superior to that of comparative examples 8 and 9.
(4) Performance results at vacuum drying temperature
TABLE 4 detection results of vacuum drying temperatures
As can be seen from Table 4, the alcohol extract and the aqueous extract of examples 1 and 7 were high in ferulic acid, osthole, gentiopicroside and gallic acid, and the content of the above components was the highest in example 1. The drying temperatures of comparative examples 10 and 11 were too low and too high, respectively, and the contents of the active ingredients in the extracts were lower than those of examples 1 and 7. It can be seen that the technical effect of the vacuum drying process of the present invention is superior to that of comparative examples 10 and 11.
(5) Performance results of the adhesive
TABLE 5 detection results of adhesives
Group of | Particle morphology |
Example 1 | The soft material has moderate viscosity, is easy to granulate and sift, and has uniform granules |
Example 8 | The soft material has moderate viscosity, is easy to granulate and screen, and has slightly bad granule color |
Comparative example 12 | Adding small amount to quickly agglomerate, become sticky, not easy to mix uniformly and difficult to granulate |
Comparative example 13 | The soft material is dry, is easy to granulate, has loose granules and too much fine powder |
As can be seen from table 5, the binders of examples 1 and 8 were able to be successfully granulated, with example 1 being the most effective. The ethanol concentrations of comparative examples 12 and 13 as binders were too low and too high, respectively, resulting in unsuccessful granulation. It can be seen that the formulation of the present invention is sensitive to ethanol concentration, either too high or too low to be successfully granulated.
(6) Performance results of the adjuvant
The composite score is calculated as follows:
composite score = molding rate/maximum molding rate x 0.5+ minimum moisture absorption rate/moisture absorption rate x 0.3+ minimum angle of repose/angle of repose x 0.2
Table 6 detection results of adjuvants
Group of | Molding rate (%) | Moisture absorption Rate (%) | Angle of repose (°) | Comprehensive scoring |
Example 1 | 94.38 | 8.73 | 20.82 | 98.66 |
Example 9 | 91.42 | 9.29 | 21.34 | 94.85 |
Example 10 | 92.60 | 8.99 | 20.79 | 96.90 |
Example 11 | 89.65 | 8.53 | 21.61 | 96.13 |
Comparative example 14 | — | — | — | — |
Comparative example 15 | — | — | — | — |
Comparative example 16 | — | — | — | — |
The auxiliary materials and the extract powder of comparative examples 14 to 16 were granulated to form a black thick paste, and were agglomerated, and were not granulated. As can be seen from Table 6, the granules obtained by the preparation methods of examples 1 and 9 to 11 were high in molding rate, low in moisture absorption rate and good in fluidity, and the effect of example 1 was the best and the composite score was the highest. Therefore, only part of medicinal fine powder is added as the filler, so that the problems of high hygroscopicity and low forming rate of the extract fine powder can be effectively solved.
Test example 2
Clinical data
1. Western diagnostic criteria
Diagnosis was made according to the relevant diagnosis criteria for rheumatoid diseases, established by the American society of rheumatology, 1987, and diagnosis of rheumatoid arthritis, therapeutic guidelines:
(1) Morning stiffness for at least 1h;
(2) 3 or more joints are involved;
(3) The joint swelling between the wrist, the metacarpophalangeal or the proximal interphalangeal is more than or equal to 6 weeks;
(4) The involvement of the symmetrical joint is more than or equal to 6 weeks;
(5) There are rheumatoid subcutaneous nodules;
(6) A hand X-ray film change;
(7) Serum rheumatoid factor positive.
The rheumatoid arthritis can be diagnosed by providing 4 or more than 4 of the 7.
2. Diagnostic criteria for traditional Chinese medicine
The diagnosis of the traditional Chinese medicine accords with cold arthralgia of the traditional Chinese medicine science and the clinical research guidelines of the new traditional Chinese medicine, and clinically manifests as cold pain and swelling of joints, increased pain when encountering cold, reduced pain, fixed pain, unfavorable flexion and extension of joints, cold limbs, white coating, wiry and tight pulse and the like.
3. Inclusion criteria: meets the Western diagnosis standard; meets the diagnostic standard of traditional Chinese medicine; the sex is unlimited, and the age is 20-70 years old; continuously taking the Chinese medicine orally and checking regularly; and signing an informed consent form.
4. Exclusion criteria: severe advanced rheumatoid arthritis, joint deformation, and inability to self-care in life; other rheumatic diseases and severe heart-lung, liver-kidney dysfunction; pregnant or lactating women; while receiving other related treatments; those treated with glucocorticoids and antirheumatic drugs (DMARDs) within 6 months; allergic to oral administration.
5. General data
Clinical observations 1081 cases were confirmed in rheumatoid arthritis patients, of which men 648 and women 433.
6. Therapeutic method
The granule prepared in example 1 was taken three times daily, 10 to 20g each time, with warm water after meals, for 3 months.
7. Efficacy assessment index
And (3) observing the indexes:
(1) Clinical symptom observation: the swelling degree, tenderness and pain point number of the joints before and after treatment are divided into 'none, mild, moderate and severe' according to the degree, and 0, 2, 4 and 6 are respectively recorded; the pain number is calculated according to the actual pain joint number; morning stiffness time is the time from morning to the time when stiffness disappears.
(2) The Chinese medicine symptoms before and after treatment are scored according to the symptoms of morning stiffness, tenderness joint number, swelling joint number, pain score and joint swelling, namely, symptoms of no, mild, moderate and severe, respectively scored for 0, 2, 4 and 6.
(3) Observing the serum inflammatory factors before and after treatment to detect the level of rheumatoid factors, C-reactive proteins and blood sedimentation;
8. curative effect judging index
And (3) healing: the clinical symptoms are obviously improved, and the laboratory indexes are recovered to be normal;
the method is effective: the clinical symptoms are partially improved, and laboratory indexes are improved;
invalidation: clinical symptoms, laboratory indexes and the like are not obviously improved, and even aggravated.
9. Therapeutic results
TABLE 7 Effect of the granules of example 1 on treating rheumatoid arthritis
Healing of the wound | Effective and effective | Invalidation of | Total effective rate |
325(30.06%) | 610(56.43%) | 146(13.51%) | 86.49% |
As shown in Table 7, the granule of the present invention cured 30.06% after treating rheumatoid arthritis, and was 56.43% effective, and the total effective rate was 86.49%. Therefore, the granule of the present invention can effectively treat rheumatoid arthritis.
The foregoing is merely a preferred embodiment of the present invention and it should be noted that modifications and adaptations to those skilled in the art may be made without departing from the principles of the present invention, which are intended to be comprehended within the scope of the present invention.
Claims (7)
1. The preparation method of the anti-rheumatism traditional Chinese medicine preparation is characterized in that the traditional Chinese medicine preparation comprises the following raw materials:
herba Erodii seu Geranii, glycyrrhrizae radix, radix Angelicae Pubescentis, radix Gentianae Marcrophyllae, ramulus Sambuci Williamsii, rhizoma corydalis, radix Angelicae sinensis and flos Matricariae Chamomillae;
the preparation method comprises the following steps:
taking 14-16 parts of geranium, 5-7 parts of liquorice and 7-9 parts of chamomile, extracting with water under reflux, and refining to obtain an aqueous extract;
taking, by weight, 11-13 parts of gentiana macrophylla, 9-11 parts of angelica sinensis, 9-11 parts of elder, 9-11 parts of corydalis tuber and 11-13 parts of radix angelicae pubescentis, and carrying out reflux extraction with an ethanol solution to obtain an ethanol extract;
concentrating the water extract and the alcohol extract under reduced pressure respectively, drying to obtain extract fine powder, adding ethanol solution with the concentration of 92-93% and fine powder of angelica and/or radix angelicae pubescentis raw materials with the total weight of 5-10% of the total weight of the extract fine powder, mixing and granulating.
2. The method of manufacturing according to claim 1, wherein the refining comprises: concentrating the water extract under reduced pressure until the ratio of the mass of the medicinal materials to the volume of the liquid medicine is 1 (1-1.2), standing, and filtering to obtain supernatant.
3. The preparation method according to claim 1, wherein the concentration of the ethanol solution is 65-75%, the volume of the added ethanol solution is 9-11 times of the weight of the raw material, and the reflux extraction is performed for 1-3 times, and each time the extraction is performed for 80-120 min.
4. The method according to claim 1, wherein the reduced pressure concentration is carried out at a temperature of 60 to 80 ℃ and the drying is carried out at a temperature of 60 to 80 ℃.
5. A Chinese medicinal preparation prepared by the preparation method of any one of claims 1 to 4.
6. The traditional Chinese medicine preparation according to claim 5, wherein the dosage form of the traditional Chinese medicine preparation comprises a emplastrum, a granule, a tablet or a capsule.
7. The use of a Chinese medicinal preparation according to claim 5 or 6 in the preparation of a medicament for the treatment of rheumatoid arthritis.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210963560.1A CN115137766B (en) | 2022-08-11 | 2022-08-11 | Preparation method of anti-rheumatism traditional Chinese medicine preparation, traditional Chinese medicine preparation and application |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210963560.1A CN115137766B (en) | 2022-08-11 | 2022-08-11 | Preparation method of anti-rheumatism traditional Chinese medicine preparation, traditional Chinese medicine preparation and application |
Publications (2)
Publication Number | Publication Date |
---|---|
CN115137766A CN115137766A (en) | 2022-10-04 |
CN115137766B true CN115137766B (en) | 2023-07-07 |
Family
ID=83415673
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210963560.1A Active CN115137766B (en) | 2022-08-11 | 2022-08-11 | Preparation method of anti-rheumatism traditional Chinese medicine preparation, traditional Chinese medicine preparation and application |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115137766B (en) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1153058A (en) * | 1996-08-25 | 1997-07-02 | 重庆祥慧医药高新技术研究所 | Prescription of Hanbi xiao granules and production process thereof |
CN101954045A (en) * | 2010-09-20 | 2011-01-26 | 广州博济新药临床研究中心有限公司 | Traditional Chinese medicinal composition for treating damp arthralgia and preparation method thereof |
CN108295128A (en) * | 2018-04-27 | 2018-07-20 | 安徽中医药大学 | A kind of compound Chinese medicinal preparation and preparation method thereof for treating rheumatoid arthritis |
-
2022
- 2022-08-11 CN CN202210963560.1A patent/CN115137766B/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1153058A (en) * | 1996-08-25 | 1997-07-02 | 重庆祥慧医药高新技术研究所 | Prescription of Hanbi xiao granules and production process thereof |
CN101954045A (en) * | 2010-09-20 | 2011-01-26 | 广州博济新药临床研究中心有限公司 | Traditional Chinese medicinal composition for treating damp arthralgia and preparation method thereof |
CN108295128A (en) * | 2018-04-27 | 2018-07-20 | 安徽中医药大学 | A kind of compound Chinese medicinal preparation and preparation method thereof for treating rheumatoid arthritis |
Non-Patent Citations (2)
Title |
---|
刘太瑞.辨证分型治疗痹证548例.《湖南中医杂志》.1997,13(2(S1)),第49页. * |
杨玉玲等.复方老鹳草方中老鹳草和甘草有效成分的水提工艺研究.《新疆医科大学学报》.2020,第43卷(第5期),第637-641页. * |
Also Published As
Publication number | Publication date |
---|---|
CN115137766A (en) | 2022-10-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107158063B (en) | Enteric-coated pellet prepared from honeysuckle effective part composition and preparation method thereof | |
CN101632827B (en) | Traditional Chinese medicine composition for treating psoriasis and preparation method thereof | |
CN110559403B (en) | Traditional Chinese medicine composition for preventing and treating hyperuricemia and preparation method and application thereof | |
CN111358839B (en) | Formula granules of polygonum capitatum and preparation method thereof | |
CN105727144A (en) | Traditional Chinese medicine composition for treating bronchitis and preparation method thereof | |
CN110755542A (en) | Formula of uric acid-reducing gout-treating tea and preparation method thereof | |
CN115137766B (en) | Preparation method of anti-rheumatism traditional Chinese medicine preparation, traditional Chinese medicine preparation and application | |
CN101829291B (en) | Traditional Chinese medicine preparation for treating rheumatism and preparation method thereof | |
CN102133273B (en) | Traditional Chinese medicine lipid-lowing and catharsis capsule and preparation method thereof | |
CN104971088A (en) | Tibetan artemisia capillaris extract and preparation method, drug composition and application thereof | |
CN105497096A (en) | Medicine composition for treating liver ascites and preparation method thereof | |
CN103393786B (en) | Drug for treating the asthma disease and preparation method thereof | |
CN103006781B (en) | Compound Dai medicine extract with liver-protecting effect and preparation method thereof | |
CN101869675B (en) | Chinese medicinal composition granules for treating summer-heat damp cold and preparation method thereof | |
CN115554325A (en) | Application of medicine terminalia fruit, extractive or preparation thereof in preparing anti-inflammatory, analgesic or uric acid-reducing medicines | |
CN103908631A (en) | Traditional Chinese medicinal compound extract with anti-breast hyperplasia effect and preparation method thereof | |
CN114344358A (en) | Eucommia ulmoides composition containing aucubin and geniposide, preparation and application | |
CN112546085A (en) | Sambucus chinensis extract for treating gout and preparation method thereof | |
CN112516262A (en) | Acid-reducing tea for relieving gout and preparation method thereof | |
CN103599259A (en) | Dai medicine extract with hypoglycemic effect, preparation and application thereof | |
CN104257755A (en) | Composition with effect of treating diabetes as well as preparation method and application of composition | |
CN104288287A (en) | Anti-inflammation sterilizing antiviral traditional Chinese medicine composition and preparation method thereof | |
CN115364179B (en) | Traditional Chinese medicine composition for reducing blood uric acid as well as preparation method and application thereof | |
CN106377651A (en) | Preparation method for extracting pharmaceutical monomer for preventing and treating hyperuricemia and gout from rhizoma smilacis glabrae | |
CN110812401A (en) | Traditional Chinese medicine composition for soft tissue injury and detection method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB03 | Change of inventor or designer information |
Inventor after: Lan Wei Inventor after: Li Jianmei Inventor before: Lan Wei Inventor before: Zheng Yuke Inventor before: Li Jianmei |
|
CB03 | Change of inventor or designer information | ||
GR01 | Patent grant | ||
GR01 | Patent grant |